KOPRAN LTD (KOPRAN) financials

KOPRAN LTD (KOPRAN) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Market Cap: ₹1,239Cr.
Current Price: ₹256
Stock P/E: 36.9
ROE: 6.91%
ROCE: 9.19%
Book Value: ₹92.8
Dividend Yield: 1.17%
52W High / Low: ₹296/107

In Jun 2026, KOPRAN LTD (KOPRAN) reported sales ₹62.76 Cr and net profit ₹6.72 Cr.

Annual TTM: sales ₹317 Cr, net profit ₹34 Cr.

Shareholding: Promoters 41.83% (Sep 2026), FIIs 0.91% (Sep 2026), DIIs 0.00% (Sep 2026), Public 57.26% (Sep 2026), No. of Shareholders 52,924% (Sep 2026).

KOPRAN quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	73.53	71.94	75.94	51.33	42.39	93.88	118.04	62.76
Expenses	63.84	60.54	63.65	46.26	45.59	76.20	91.45	54.30
Operating Profit	9.69	11.40	12.29	5.07	-3.20	17.68	26.59	8.46
OPM %	13.18%	15.85%	16.18%	9.88%	-7.55%	18.83%	22.53%	13.48%
Other Income	1.12	0.75	1.92	1.80	0.32	0.32	1.00	2.91
Interest	0.83	0.99	1.26	1.04	0.83	1.16	1.17	1.24
Depreciation	1.23	1.33	1.24	1.22	1.16	1.25	1.34	1.35
Profit before tax	8.75	9.83	11.71	4.61	-4.87	15.59	25.08	8.78
Tax %	24.57%	24.62%	26.56%	23.64%	-18.07%	22.13%	25.24%	23.46%
Net Profit	6.60	7.41	8.60	3.52	-3.99	12.13	18.74	6.72
EPS in Rs	1.37	1.54	1.78	0.73	-0.83	2.51	3.88	1.39
Raw PDF	—	—	—	—	—	—	—	—

KOPRAN profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	179	223	205	273	337	271	306	317
Expenses	156	193	189	245	301	232	258	268
Operating Profit	23	30	15	28	37	39	48	50
OPM %	13%	14%	8%	10%	11%	14%	16%	16%
Other Income	2	10	8	16	17	6	2	5
Interest	6	4	3	3	4	4	4	4
Depreciation	3	4	4	4	5	5	5	5
Profit before tax	16	33	16	37	45	36	40	45
Tax %	29%	28%	27%	15%	22%	25%	25%	—
Net Profit	11	23	12	31	35	27	30	34
EPS in Rs	2.59	5.43	2.44	6.48	7.19	5.57	6.30	6.95
Dividend Payout %	-0%	55%	123%	46%	42%	54%	48%	—

KOPRAN balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	43	43	43	48	48	48	48	48
Reserves	175	186	204	331	347	369	383	400
Borrowings	50	46	16	37	28	23	45	46
Other Liabilities	50	52	61	48	82	71	70	112
Total Liabilities	319	327	324	464	506	511	546	606
Fixed Assets	42	43	47	46	47	52	61	82
CWIP	7	7	3	3	4	5	7	8
Investments	158	158	159	259	260	261	263	265
Other Assets	112	119	115	155	195	193	215	252
Total Assets	319	327	324	464	506	511	546	606

KOPRAN cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	12	10	49	-38	17	35	23	30
Cash from Investing Activity	-4	1	-9	-100	10	-6	-15	-30
Cash from Financing Activity	-7	-11	-40	138	-26	-24	6	-19
Net Cash Flow	-0	-0	0	-0	1	5	14	-19
Free Cash Flow	6	5	44	-41	11	24	6	4
CFO/OP	69%	60%	179%	-222%	83%	121%	86%	71%

KOPRAN shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	44.45%	44.42%	44.43%	44.43%	44.43%	44.43%	44.43%	41.83%
FIIs	0.86%	1.11%	0.76%	0.60%	0.36%	0.57%	0.51%	0.91%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	54.68%	54.45%	54.81%	54.99%	55.21%	55.01%	55.06%	57.26%
No. of Shareholders	60,560	58,652	60,194	62,222	60,886	58,639	56,925	52,924

KOPRAN key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	83	86	81	106	112	95	124	158
Inventory Days	78	149	73	119	98	78	129	141
Days Payable	101	114	106	85	128	82	108	162
Cash Conversion Cycle	60	121	48	139	82	91	145	137
Working Capital Days	59	59	64	129	116	104	114	109
ROCE %	9%	8%	14%	6%	9%	11%	9%	9%

KOPRANUpdated 13 Oct 2026, 14:11

Kopran Ltd

KOPRANUpdated 13 Oct 2026, 14:11

Market Cap

₹1,239Cr.

Current Price

₹256

High / Low

₹296/107

Stock P/E

36.9

ROE6.91%

ROCE9.19%

Book Value₹92.8

Face Value₹10.0

Dividend Yield1.17%

About

Kopran Ltd. is a fully integrated pharmaceutical company that manufactures and supplies high-quality formulations and active pharmaceutical ingredients globally.

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	65.86	0.95	65.04	1.48	1.12	0.23	30.43	0.15	0.03
Sep 2023	98.64	0.74	89.94	5.79	1.16	12.59	15.25	10.66	2.21
Dec 2023	82.33	1.02	70.27	1.29	1.17	11.16	23.75	8.51	1.77
Mar 2024	90.62	1.78	75.28	8.15	1.16	20.55	25.5	15.31	3.18
Jun 2024	49.61	0.69	44.33	2.12	1.2	5.51	23.05	4.25	0.88
Sep 2024	73.53	0.83	63.84	1.12	1.23	8.75	24.57	6.6	1.37
Dec 2024	71.94	0.99	60.54	0.75	1.33	9.83	24.62	7.41	1.54
Mar 2025	75.94	1.26	63.65	1.92	1.24	11.71	26.56	8.6	1.78
Jun 2025	51.33	1.04	46.26	1.8	1.22	4.61	23.64	3.52	0.73
Sep 2025	42.39	0.83	45.59	0.32	1.16	-4.87	-18.07	-3.99	-0.83
Dec 2025	93.88	1.16	76.2	0.32	1.25	15.59	22.13	12.13	2.51
Mar 2026	118.04	1.17	91.45	1	1.34	25.08	25.24	18.74	3.88
Jun 2026	62.76	1.24	54.3	2.91	1.35	8.78	23.46	6.72	1.39

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015	326	13	294	6	10	15	0	15	3.77
Mar 2016	187	10	162	0	3	11	0	11	2.64
Mar 2017	182	10	164	9	3	13	36	8	1.97
Mar 2018	154	7	145	8	3	7	32	5	1.09
Mar 2019	197	5	174	3	3	17	25	13	3
Mar 2020	179	6	156	2	3	16	29	11	2.59
Mar 2021	223	4	193	10	4	33	28	23	5.43
Mar 2022	205	3	189	8	4	16	27	12	2.44
Mar 2023	273	3	245	16	4	37	15	31	6.48
Mar 2024	337	4	301	17	5	45	22	35	7.19
Mar 2025	271	4	232	6	5	36	25	27	5.57
Mar 2026	306	4	258	2	5	40	25	30	6.3
TTM	317	4	268	5	5	45	—	34	6.95

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	41.83%
FIIs	0.91%
Public	57.26%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Public
Dec 2023	44.49%	0.48%	0.14%	54.88%
Mar 2024	44.49%	0.84%	1.2%	53.47%
Jun 2024	44.49%	0.68%	0.14%	54.68%
Sep 2024	44.49%	1.31%	0.22%	53.98%
Dec 2024	44.45%	0.86%	0%	54.68%
Mar 2025	44.42%	1.11%	0%	54.45%
Jun 2025	44.43%	0.76%	0%	54.81%
Sep 2025	44.43%	0.6%	0%	54.99%
Dec 2025	44.43%	0.36%	0%	55.21%
Mar 2026	44.43%	0.57%	0%	55.01%
Jun 2026	44.43%	0.51%	0%	55.06%
Sep 2026	41.83%	0.91%	0%	57.26%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	41	136	46	51	275	33	0	46	195	275
Mar 2016	43	145	42	49	279	35	0	156	88	279
Mar 2017	43	158	56	54	311	39	4	157	110	311
Mar 2018	43	162	52	42	300	38	8	157	97	300
Mar 2019	43	175	50	50	319	42	7	158	112	319
Mar 2020	43	186	46	52	327	43	7	158	119	327
Mar 2021	43	204	16	61	324	47	3	159	115	324
Mar 2022	48	331	37	48	464	46	3	259	155	464
Mar 2023	48	347	28	82	506	47	4	260	195	506
Mar 2024	48	369	23	71	511	52	5	261	193	511
Mar 2025	48	383	45	70	546	61	7	263	215	546
Mar 2026	48	400	46	112	606	82	8	265	252	606

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	53	-10	-43	0
Mar 2016	19	-4	-15	0
Mar 2017	4	-9	5	0
Mar 2018	12	-2	-11	0
Mar 2019	12	-4	-7	0
Mar 2020	10	1	-11	0
Mar 2021	49	-9	-40	0
Mar 2022	-38	-100	138	0
Mar 2023	17	10	-26	1
Mar 2024	35	-6	-24	5
Mar 2025	23	-15	6	14
Mar 2026	30	-30	-19	-19

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	33	38	77	48	83	86	81	106	112	95	124	158
Inventory Days	24	90	84	119	78	149	73	119	98	78	129	141
Days Payable	63	114	120	115	101	114	106	85	128	82	108	162
Cash Conversion Cycle	-6	14	41	52	60	121	48	139	82	91	145	137
Working Capital Days	124	41	46	49	59	59	64	129	116	104	114	109
ROCE %	11%	10%	10%	5%	9%	8%	14%	6%	9%	11%	9%	9%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of KOPRAN LTD (KOPRAN)?

The reported market capitalisation for KOPRAN LTD (KOPRAN) is ₹1,239Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of KOPRAN?

The current price shown for KOPRAN LTD (KOPRAN) on Fincrux is ₹256 with a 52-week high/low of ₹296/107.

What is the P/E ratio of KOPRAN LTD (KOPRAN)?

The stock P/E for KOPRAN LTD (KOPRAN) is 36.9 on Fincrux, with ROE at 6.91% and ROCE at 9.19%.

What were KOPRAN latest quarterly results?

For Jun 2026, KOPRAN LTD (KOPRAN) reported sales ₹62.76 Cr and net profit ₹6.72 Cr (figures in ₹ crore unless noted).

What are KOPRAN annual sales and net profit?

For TTM, KOPRAN LTD (KOPRAN) shows sales of ₹317 Cr and net profit of ₹34 Cr on the Fincrux profit & loss statement.

Who owns KOPRAN LTD (KOPRAN)?

Latest shareholding for KOPRAN LTD (KOPRAN) on Fincrux: Promoters 41.83% (Sep 2026), FIIs 0.91% (Sep 2026), DIIs 0.00% (Sep 2026), Public 57.26% (Sep 2026), No. of Shareholders 52,924% (Sep 2026).

Where can I find KOPRAN LTD (KOPRAN) financials?

KOPRAN LTD (KOPRAN) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show KOPRAN balance sheet and cash flow?

Yes. The KOPRAN LTD (KOPRAN) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 13 October 2026 at 14:11